
Survodutide cuts visceral fat by 34% and liver fat by 63%, boosting metabolic health in obesity Phase III trials.
Boehringer Ingelheim's Phase III trials of survodutide, a glucagon/GLP-1 dual agonist, showed significant metabolic health improvements in people with obesity. The SYNCHRONIZE-1 trial reported up to 16.6% weight loss, 34% reduction in visceral fat, a...

